Welcome to the Lilly Scientific Information Page for AAN 2026
American Academy of Neurology
Chicago, Illinois
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn
Disclosures
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Curt Schreiber
- Molecule(s): Donanemab
Characterization of 'Early-Start' Participants that Continued Receiving Donanemab in the TRAILBLAZER-ALZ 2 Long-Term Extension Period
Trial(s) Overview:
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Traci Schilling
- Molecule(s): Donanemab
Characterization of 'Early-Start' Participants that Continued Receiving Donanemab in the TRAILBLAZER-ALZ 2 Long-Term Extension Period
Trial(s) Overview:
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Cynthia Sandoval
- Molecule(s): Not Applicable
A Novel Prospective Study Design Evaluating Impact of Plasma P-tau217 Testing on Early Evaluation and Management of Patients in Primary and Secondary/Tertiary Care Private Practices
Trial(s) Overview:
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)